Metabolic screening for patients with second-generation antipsychotic medication: A population-based study from 2004 to 2016
Patients with severe mental disorders have excess mortality due to preventable physical diseases, especially cardiovascular disease (Crump et al., 2013). One of the major risk factors for cardiovascular diseases is metabolic syndrome (Kaur, 2014), yet it has been reported that the prevalence for patients to develop metabolic syndrome doubles that of the general population (Riordan et al., 2011). A link between second-generation antipsychotic medications and the increased risk for both metabolic and cardiovascular abnormalities has been proposed (De Hert et al., 2012).
AbstractFew studies have investigated the longitudinal effects of treatment-emergent metabolic syndrome changes on cognitive performance in first-episode psychosis. The aim of the present study was to determine the associations between changes in metabolic syndrome constituent component over 12 months of treatment and end-point cognitive performance in schizophrenia spectrum disorders. This single site-cohort study included 72 minimally treated or antipsychotic-naïve first-episode patients. Cognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). Our pri mary objective of interes...
CONCLUSION: Prediabetes and metabolic abnormalities were highly prevalent among the clozapine- and olanzapine-treated patients with schizophrenia, putting these patients at great risk for later type 2 diabetes and cardiovascular disease. These results stress the importance of identifying and adequately treating prediabetes and metabolic abnormalities among clozapine- and olanzapine-treated patients with schizophrenia. PMID: 30596361 [PubMed - as supplied by publisher]
Conclusion: Results of the present study suggest that metabolic syndrome in participants taking second-generation antipsychotics is mediated through OSA. PMID: 30581214 [PubMed]
Andrea Schmitt, Isabel Maurus, Moritz J. Rossner, Astrid R öh, Moritz Lembeck, Martina von Wilmsdorff, Shun Takahashi, Boris Rauchmann, Daniel Keeser, Alkomiet Hasan, Berend Malchow, Peter Falkai
People with severe mental illness (SMI), such as schizophrenia or other long-term psychotic conditions, experience an increased risk of physical ill health and premature death, with an average life expectancy 10 –25 years shorter than the general population (Laursen, Munk-Olsen,&Vestergaard, 2012). This higher risk of morbidity and mortality for people with SMI is related to the increased risk of developing metabolic syndrome (McDaid&Smyth, 2015). The prevalence of diabetes and cardiovascular diseases among people with SMI is greater than in the general population (Lahti et al., 2012; Stubbs, Vancampfort, D...
Marta Bosia, Mariachiara Buonocore, Margherita Bechi, Laura Santarelli, Marco Spangaro, Federica Cocchi, Carmelo Guglielmino, Laura Bianchi, Serena Bringheli, Francesca Bosinelli, Roberto Cavallaro
This study employed a randomized placebo-controlled trial to investigate the effects of omega-3 fatty acids on MetS in patients with schizophrenia.MethodsWe recruited 80 patients with both schizophrenia and MetS who received long-term olanzapine monotherapy. The patients were randomly assigned to the OMG-3 group (n = 40) or the placebo group (n = 40).ResultsPatients with both schizophrenia and MetS had significantly higher levels of TNF-alpha than the control subjects (Z = − 4.37,P
CONCLUSION: Older patients with schizophrenia treated with antipsychotics within an ICP experience higher rates of monitoring and less psychotropic polypharmacy than older patients treated with antipsychotics under TAU conditions. These findings suggest that an ICP can improve the quality of antipsychotic pharmacotherapy in older patients and thus possibly its effectiveness. This needs to be confirmed by a randomized controlled trial. PMID: 30396766 [PubMed - as supplied by publisher]
Publication date: Available online 4 November 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Shazia Anjum, Manish BathlaAbstractBackgroundExponential growth of metabolic syndrome in psychiatric disorders is becoming alarming situation to handle with. It is associated with reduced life span of 10–30 years in psychiatric patients attributed to metabolic syndrome, thus needs to be screened and addressed in all psychiatric patients.Objectivethe objective of this study was to know the prevalence and its risk factors in various psychiatric disorder and comparing them in older vs youn...
CONCLUSIONS: There is a high prevalence of sexual dysfunction in the patients with schizophrenia who participated in the study, but it was only associated with higher age, being single or divorced or having depressive psychopathology; this suggests a multifactorial etiology for sexual dysfunction in schizophrenia. PMID: 30552811 [PubMed - in process]